American Society of Hematology/LinkedIn
Oct 1, 2026, 14:39
Understanding the FDA Pathway for Hematology Product Development – American Society of Hematology
American Society of Hematology shared a post on LinkedIn:
“Over the past two days, ASH and the FDA convened the ASH-FDA Collaboration: Workshop on Regulatory Science in Hematology, an interactive program designed to deepen participants’ understanding of the FDA’s role in hematology product development.
Participants explored the FDA’s role in hematology product development through dynamic panels, case studies, and discussions on the IND process, clinical trial design, expanded access, expedited development programs, and regulatory review.
Learn more about the workshop.”

Other posts featuring American Society of Hematology on Hemostasis Today.
-
Nov 10, 2026, 16:28Can the VWF to ADAMTS-13 Ratio Predict Mortality in Sepsis-Induced Coagulopathy? – RPTH Journal
-
Nov 10, 2026, 16:28Ruth Willems: PhD Defence at Maastricht University on Thrombosis and Bleeding in HPB Disease
-
Nov 10, 2026, 16:09Edward Lee Carter: Factor XIa Inhibition Enters Clinical Practice
-
Nov 10, 2026, 16:08Edward C.C. Wong: Deriving Ferritin Cutoffs for Iron Deficiency Using RBC Parameters
-
Nov 10, 2026, 16:07Milad Abdalla: Decoding Hemoglobin Electrophoresis – A Practical Diagnostic Reference
-
Nov 10, 2026, 15:13Wolfgang Miesbach: Nonviral Gene Therapy for Haemophilia A Using Lipid Nanoparticles
-
Nov 10, 2026, 15:06Dahra Teles: First Speaking Experience at HEMO 2026 on First-Line Multiple Myeloma Treatment
-
Nov 10, 2026, 14:55Yazan Abou-Ismail: First FDA-Approved Factor XIa Inhibitor for Stroke Prevention
-
Nov 10, 2026, 14:49Ifeanyichukwu Ifechidere: The Role of Coagulation in Anaesthesia and Surgery